Novocure (NVCR) overview updated February 2018
|
|
- Tyrone Gaines
- 6 years ago
- Views:
Transcription
1 Novocure (NVCR) overview updated February 2018
2 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology indications. These forward-looking statements can be identified in this presentation by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words expect, intend, anticipate, plan, may, should, would, could or other words of similar meaning. These statements are based on assumptions and assessments made by Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and financial results could differ materially from those expressed or implied in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, or in subsequent quarterly filings with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Novocure assumes no obligation to update or correct the information contained in this presentation, whether as a result of new information, future events or otherwise, except to the extent legally required. The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated. As of the date of this presentation, Optune is only FDA-approved for the treatment of adults with supratentorial glioblastoma, or GBM, and its approval for other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune or its successful commercialization, and can provide no assurances regarding the company s results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security. 2
3 Optune indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy. For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. CONTRAINDICATIONS Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure. 3
4 Optune indications for use and important safety information WARNINGS AND PRECAUTIONS Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer). Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established. The most common ( 10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression. The most common ( 10%) adverse events seen with Optune monotherapy were medical device site reaction and headache. The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer. Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective. If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment. 4
5 a global oncology company with a proprietary platform GROWING COMMERCIAL BUSINESS More than 1,800 patients on therapy 12 consecutive quarters of patient growth $177 million trailing twelve month revenues Information above as of December 31, 2017 SIGNIFICANT UPSIDE POTENTIAL Increase adoption and average reimbursement in GBM Advance clinical pipeline in five additional solid tumor indications 5
6 evolving treatment paradigms for solid tumor cancers USED ALONE OR IN COMBINATION TO TREAT SOLID TUMORS surgery radiation pharmacological treatments tumor treating fields (TTFields) Reduces size of a tumor prior to initiation of additional therapies Invasive to patient Unable to kill microscopic disease Kills cells when delivered at high doses Injures healthy tissues as well as cancer cells Numerous potentially toxic side effects Includes chemotherapy, targeted therapies and immuno-oncology Many treatments target specific patient subgroups Frequently accompanied by numerous side effects Electric fields tuned to specific frequencies Disrupts solid tumor cancer cell division Mild side effect profile with no known cumulative toxicity 6
7 we can leverage physics to fight cancer AN ELECTRIC FIELD EXERTS FORCES ON CHARGED OBJECTS TUMOR TREATING FIELDS USES ELECTRIC FIELDS TO DISRUPT CELL DIVISION MISALIGNED TUBULINS INTERFERE WITH FORMATION OF MITOTIC SPINDLE ALTERNATING ELECTRIC FIELDS DISRUPT CANCER CELL DIVISION MISALIGNED SEPTINS INTERFERE WITH FORMATION OF CONTRACTILE RING TUMOR TREATING FIELDS DESCRIBES ELECTRIC FIELDS THAT ALTERNATE 100,000 TO 300,000 TIMES PER SECOND TO TARGET CANCER CELLS CANCER CELL DEATH 7
8 broad applicability to solid tumors INDICATIONS IN-VITRO EVIDENCE IN-VIVO EVIDENCE FIRST IN HUMAN EVIDENCE Glioblastoma Malignant melanoma Non-small cell lung cancer Pancreatic cancer Breast cancer Mesothelioma Ovarian carcinoma Renal adenocarcinoma Cervical cancer Colorectal carcinoma Ependymoma Gastric adenocarcinoma Gliosarcoma Hepatocellular carcinoma Medulloblastoma Meningioma Small cell lung cancer Urinary transitional cell carcinoma 8
9 proven superior long-term survival with Optune plus temozolomide in GBM 1 Probability of survival TMZ alone 31% Intent-to-treat population 1 Median OS from Optune TMZ (n=466) randomization (months) TMZ alone (n=229) Stratified log-rank p= Optune + TMZ 43% p=0.001 HR (95% CI) 0.63 ( ) Median OS from diagnosis (months) Optune + TMZ 13% p= Overall Survival (months) 5% TMZ alone 1. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor- Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):
10 Optune plus TMZ consistently sustained superior rates of survival FIVE-YEAR SURVIVAL INTENT-TO-TREAT ANALYSIS 1 100% 90% 80% p=0.029 Optune + TMZ (n=466) TMZ alone (n=229) Survival rate (%) 70% 60% 50% 40% 30% 20% 10% 0% 73% 65% p= % p=0.004 p= % 26% p= % 16% 13% 8% 5% Year from randomization 1. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):
11 patients with increased compliance had increased survival benefit FIVE-YEAR SURVIVAL ANALYSIS IN MOST COMPLIANT PATIENTS (>90%) 1 100% 90% 80% Optune > 90% compliance + temozolomide (n=43) temozolomide alone (n=229) 86% Survival rate (%) 70% 60% 50% 40% 30% 20% 65% 55% 31% 29% 29% 29% 10% 0% 16% 8% 5% Year from randomization 1. Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017; San Francisco, CA. Oral presentation ACTR
12 ADULT PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED GBM global commercial presence global active markets as of December 31, 2017 ADULT PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED GBM UNITED STATES 49 sales force colleagues UNITED STATES 714 certified centers EMEA 245 certified centers EMEA 10 sales force colleagues JAPAN 2 sales force colleagues JAPAN 163 certified centers certified centers sales force colleagues 12
13 successful commercial launch in GBM active patients at period end ,091 1,266 1,460 1,683 1, CONSECUTIVE QUARTERS OF ACTIVE PATIENT GROWTH SINCE INITIAL PRESENTATION OF EF-14 DATA 7,000+ PATIENTS TREATED TO DATE GLOBALLY 0 Q Q Q Q Q Q Q Q Q Q Q Q U.S. active patients EMEA and Japan active patients 13
14 ongoing clinical trials PRECLINICAL PHASE II PILOT PHASE III PIVOTAL MILESTONES Brain metastases METIS trial last patient in 2019 with final data collection in 2020 Non-small cell lung cancer LUNAR trial last patient in 2019 with final data collection in 2021 Pancreatic cancer PANOVA 3 trial last patient in 2020 with final data collection in 2022 Ovarian cancer phase three pivotal trial first patient in 2H 2018 Mesothelioma STELLAR trial final data collection in 1H 2018 Trial ongoing Trial complete 14
15 addressing large market segments with significant unmet medical needs BRAIN METASTASES NON-SMALL CELL LUNG CANCER PANCREATIC CANCER OVARIAN CANCER MESOTHELIOMA 258,000 CASES DIAGNOSED ANNUALLY IN TARGET MARKETS 1 659,000 CASES DIAGNOSED ANNUALLY IN TARGET MARKETS ,000 CASES DIAGNOSED ANNUALLY IN TARGET MARKETS ,000 CASES DIAGNOSED ANNUALLY IN TARGET MARKETS ,000 CASES DIAGNOSED ANNUALLY IN TARGET MARKETS 3,6-7 ~25% OF NSCLC PATIENTS DEVELOP BRAIN METS 2 24% FIVE YEAR SURVIVAL 3 8% FIVE YEAR SURVIVAL 3 47% FIVE YEAR SURVIVAL 3 9% FIVE YEAR SURVIVAL 3 1. Goetz P, Ebinu JO, Roberge D, Zadeh G. Current Standards in the Management of Cerebral Metastases. Intl J of Surg Onc. 2012;2012: doi: /2012/ Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Frontiers in Oncology. 2014;4:248. doi: /fonc Howlader N, Noone AM, et al. SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD, based on November 2016 SEER data submission, posted to SEER web site, April Ferlay J, Steliarova-Foucher E, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in Eur J Cancer. 2013;49(6): doi: /j.ejca WHO (2016) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012, Lyon, France (accessed January 2018). 6. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79: doi: /sj.bjc Robinson B.M. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012; 1(4): doi: /j.issn X
16 demonstrated financial performance global net revenues (USD in thousands) $60,000 $50,000 $40,000 $34,880 $38,376 $50,109 77% $53,661 Q VERSUS Q YEAR-OVER-YEAR REVENUE GROWTH $30,000 $30,242 $20,000 $10,000 $0 $21,674 $17,919 $12,383 $13,053 $8,953 $5,208 $6,543 Q Q Q Q Q Q Q Q Q Q Q Q $33,087 $82,888 $177,026 FY 2015 FY 2016 FY 2017 U.S. net revenues EMEA and Japan net revenues $183.3 MILLION IN CASH AND SHORT-TERM EQUIVALENTS AS OF DECEMBER 31,
17 q selected financial highlights U.S. DOLLARS IN THOUSANDS Q Q % GROWTH Net revenues $ 53,661 $ 30,242 77% Cost of revenues 15,640 10,973 43% Gross profit 38,021 19,269 97% Research, development and clinical trials 10,048 8,471 19% Sales and marketing 16,025 15,678 2% General and administrative 16,454 12,997 27% Total operating costs and expenses 42,527 37,146 14% ESTIMATE THAT GLOBAL NET REVENUES WILL BE APPROXIMATELY 45% OF GLOBAL GROSS BILLINGS IN 2018 Operating income (loss) (4,506) (17,877) 75% Financial expenses, net 2,384 2,854-16% Income (loss) before income taxes (6,890) (20,731) 67% Income tax expense 4,055 1, % Net income (loss) $ (10,945 ) $ (22,168 ) 51% Cash and cash equivalents $ 78,592 $ 99,780 Short-term investments 104, ,854 17
18 long term value creation beyond 2018 near-term opportunity Drive commercial adoption of Optune within GBM Expand coverage for GBM patients in currently active markets and establish access for GBM patients in new markets Progress mesothelioma towards commercialization Advance the clinical pipeline in multiple solid tumor indications Grow annual revenues while improving SG&A operating leverage long-term opportunity Launch Tumor Treating Fields platform for additional indications in large addressable markets Brain metastases from non-small cell lung cancer Non-small cell lung cancer Pancreatic cancer Ovarian cancer 18
19 commercial appendix
20 direct-to-patient distribution model PHYSICIAN SENDS PHYSICIAN OR NOVOCURE NOVOCURE NOVOCURE BILLS PHYSICIAN SEES PRESCRIPTION NOVOCURE USES DELIVERS OPTUNE PROVIDES 24/7 THIRD-PARTY PATIENT FOR ORDER TO NOVOCURE NOVOTAL SYSTEM TO CREATE ARRAY PLACEMENT MAP AND TRAINS PATIENT/FAMILY TECH SUPPORT AND SUPPLIES TRANSDUCER PAYER AND PATIENT 1 FOR EACH MONTH OF REGULAR COMPLIANCE MONITORING AND ARRAYS THERAPY FOLLOW-UP APPOINTMENTS NOVOCURE Novocure distributes product through hospitals in Japan. 1. Subject to patient assistance programs. 20
21 established U.S. commercial market access >210 96% MILLION COVERED LIVES IN THE U.S. AS OF DECEMBER 31, 2017 >178 MILLION CONTRACTED LIVES IN THE U.S. AS OF DECEMBER 31, 2017 OF AMERICANS WITH PRIVATE HEALTH INSURANCE 1,2 NOW HAVE POSITIVE COVERAGE OF OPTUNE 1. U.S. population insured with employers, non-group insurance or Medicare Advantage plans 2. Appealing Medicare fee-for-service denials, impacting 20-25% of U.S. active patients 21
22 expanding global commercial market access MARKET STATUS REIMBURSEMENT STATUS Japan Austria United States Germany Commercial launch underway Commercial launch underway POSITIVE NATIONAL REIMBURSEMENT DECISIONS National reimbursement contract signed in Q National reimbursement contract signed in Q GBM MARKET SIZE ESTIMATION 1,500 annual cases diagnosed 280 annual cases diagnosed ONGOING DIALOGUES WITH GOVERNMENT PAYERS IN THE UNITED STATES, GERMANY, SWITZERLAND AND ISRAEL No material payments from Medicare to date Receive reimbursement on case-by-case basis In active discussions with CMS administration Pathway for national reimbursement established Q via G-BA budgeted clinical trial (expected to begin 2H 2018) Switzerland Single-payer system Pursuing national reimbursement Israel No material payments to date Pursuing national reimbursement 12,500 annual cases diagnosed 3,600 annual cases diagnosed 300 annual cases diagnosed 280 annual cases diagnosed 22
23 clinical appendix
24 TTFields are frequency-tuned to cell size to maximize effects on mitosis EFFECTS ON CELLS ARE FREQUENCY SPECIFIC AND INVERSELY RELATED TO CELL SIZE Normal Intestine Pancreatic Cancer NSCLC Ovarian Cancer GBM ~50 khz 150 khz 150 khz 200 khz 200 khz 24
25 transducer array placement abdominal array placement torso array placement pelvic array placement 25
26 EF-14 TRIAL IN NEWLY DIAGNOSED GLIOBLASTOMA compliance effects on overall survival 1 A trend in favor of longer overall survival was seen with higher compliance A threshold value of 50% average monthly compliance with Tumor Treating Fields was needed to show an extension of overall survival (HR 0.67, 95% CI ) compared to temozolomide alone Both progression-free survival and overall survival were extended with increased compliance beyond 50% 1. Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017; San Francisco, CA. Oral presentation ACTR
27 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER METIS phase 3 pivotal trial initiated in 2016 A prospective, randomized controlled, multicenter trial testing efficacy, safety and neurocognitive outcomes of TTFields at 150 khz following stereotactic radiosurgery for 1-10 brain metastases from non-small cell lung cancer 270 patients internationally, randomized 1:1 (TTFields vs supportive care) Last patient enrollment expected in 2019, twelve month follow-up after final patient enrollment Primary endpoint time to first intracranial progression Secondary endpoints include neurocognitive failure, overall survival, radiological response rate screening and baseline evaluation randomization 1:1 stereotactic radiosurgery stereotactic radiosurgery ttfields supportive care MRI q2m until progression MRI q2m until progression Novocure, Ltd. Effect of TTFields (150 khz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT
28 SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER phase 2 pilot EF-15 trial A prospective, open label, single-arm, non-randomized, multicenter study testing safety and preliminary efficacy of TTFields at 150 khz together with pemetrexed in pretreated patients with locally advanced and/or metastatic non-small cell lung cancer versus historical controls 42 patients in Switzerland with locally advanced and/or metastatic non-small cell lung cancer Last patient enrolled May 2011 with six month follow-up, data published in Lung Cancer in 2013 EFFICACY ENDPOINTS TTFIELDS WITH PEMETREXED 1 PEMETREXED-ALONE HISTORICAL RESULTS 2 Median in-field PFS 6.5 months n/a Median PFS 5 months 2.9 months Median OS 13.8 months 8.3 months One-year survival rate 57% 29.7% Novocure, Ltd. NovoTTF-100L in Combination With Pemetrexed (Alimta ) for Advanced Non-small Cell Lung Cancer In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT Pless M., Droege C., von Moos R., et al. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer Sep;81(3): doi: /j.lungcan Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol May 1;22(9): doi: /JCO
29 SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER LUNAR phase 3 pivotal trial initiated in 2017 A prospective, randomized controlled, multicenter trial testing efficacy and safety of TTFields at 150 khz in combination with docetaxel or immune checkpoint inhibitors for stage IV NSCLC patients following progression while on or after platinum based treatment 534 patients (TTFields plus docetaxel or immune checkpoint inhibitors vs docetaxel or immune checkpoint inhibitors alone) Last patient enrollment expected in 2019, eighteen month follow-up after final patient enrollment Primary endpoint overall survival (OS) (superiority) Secondary endpoints OS of TTFields + docetaxel vs docetaxel alone (superiority) OS of TTFields + immune checkpoint inhibitors vs immune checkpoint inhibitors alone (superiority) OS of TTFields + docetaxel vs immune checkpoint inhibitors alone (non-inferiority) progression on or after platinumbased therapy screening and baseline evaluation randomization 1:1 ttfields + immune checkpoint inhibitor/docetaxel immune checkpoint inhibitor/docetaxel CT q6w until progression CT q6w until progression three postprogression follow-up visits three postprogression follow-up visits survival follow up survival follow up Novocure, Ltd. Effect of Tumor Treating Fields (TTFields) (150 khz) as Second Line Treatment of Non-small Cell Lung Cancer (NSCLC) in Combination With PD-1 Inhibitors or Docetaxel (LUNAR) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT
30 LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCER phase 2 pilot PANOVA trial A prospective, open label, single-arm, non-randomized, multicenter study testing feasibility, safety and preliminary efficacy of TTFields at 150 khz together with gemcitabine or gemcitabine plus nabpaclitaxel in patients with advanced pancreatic cancer versus historical controls 40 patients (2 cohorts of 20 patients) in Europe with advanced pancreatic cancer Last patient enrolled May 2016 with six month follow-up EFFICACY ENDPOINTS TTFIELDS WITH GEMCITABINE 1 GEMCITABINE-ALONE HISTORICAL RESULTS 2 TTFIELDS WITH NAB-PACLITAXEL + GEMCITABINE 3 NAB-PACLITAXEL + GEMCITABINE HISTORICAL RESULTS 2 Median PFS 8.3 months 3.7 months 12.7 months 5.5 months Median OS 14.9 months 6.7 months Not yet reached 8.5 months One-year survival rate 55% 22% 72% 35% Partial response rate 30% 7% 40% 23% Stable disease 30% 28% 47% 27% Novocure, Ltd. Safety Feasibility and Effect of TTFields (150 khz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT Rivera F., et al. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. In: 2016 Gastrointestinal Cancers Symposium; 2016 Jan 21-23; San Francisco, CA. Alexandria (VA): ASCO; Abstract Von Hoff D.D., Ervin T., Arena F.P., et al. Increased Survival in Pancreatic Cancer with nab-paclitaxel plus Gemcitabine. N Engl J Med Oct 31;369(18): doi: /NEJMoa Benavides M. et.al. PANOVA: A phase II study of TTFields (150kHz) concomitant with standard chemotherapy for front line therapy of advanced pancreatic adenocarcinoma In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Abstract CT
31 LOCALLY ADVANCED PANCREATIC CANCER PANOVA 3 pivotal trial initiated in 2017 A prospective, randomized controlled, multicenter trial testing efficacy and safety of TTFields at 150 khz together with nab-paclitaxel plus gemcitabine as first-line treatment in patients with unresectable, locally advanced pancreatic cancer 556 patients internationally, randomized 1:1 (TTFields plus nab-paclitaxel plus gemcitabine vs nabpaclitaxel plus gemcitabine alone) Last patient enrollment expected in 2020, eighteen month follow-up after final patient enrollment Primary endpoint overall survival (OS) Secondary endpoints include PFS, objective response rate, rate of resectability, quality of life screening and baseline evaluation randomization 1:1 ttfields + nab-paclitaxel + gemcitabine nab-paclitaxel + gemcitabine CT q8w until progression CT q8w until progression second line chemotherapy second line chemotherapy survival follow up survival follow up Novocure, Ltd. Effect of Tumor Treating Fields (TTFields, 150 khz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT
32 RECURRENT OVARIAN CANCER phase 2 pilot INNOVATE trial A prospective, open label, single-arm, non-randomized, multicenter study testing feasibility, safety, toxicity and preliminary efficacy of TTFields at 200 khz together with weekly paclitaxel in patients with recurrent ovarian cancer versus historical controls 30 patients in Europe with recurrent ovarian cancer Last patient enrolled May 2016 with six month follow-up EFFICACY ENDPOINTS TTFIELDS WITH PACLITAXEL 1 PACLITAXEL-ALONE HISTORICAL RESULTS 2 Median PFS 8.9 months 3.9 months * Median OS Not yet reached 13.2 months One-year survival rate 61% Novocure, Ltd. Safety, Feasibility and Effect of TTFields (200 khz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT Vergote I., et.al. INNOVATE: a phase II study of TTFields (200 khz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Abstract CT Poveda A.M., Selle F., Hiplert F. et al. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J of Clin Onc Nov 10;33(32): doi: /JCO * Median PFS reflects the weekly paclitaxel subgroup; Median PFS for all chemotherapies was 3.4 months 32
33 FIRST LINE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA phase 2 pilot STELLAR trial A prospective, open label, single-arm, non-randomized, multicenter study testing safety and preliminary efficacy of TTFields at 150 khz together with pemetrexed and cisplatin or carboplatin in patients with previously untreated malignant pleural mesothelioma versus historical controls 80 patients in Europe with unresectable, previously untreated malignant mesothelioma Last patient enrolled March 2017 with twelve month follow-up, interim data presented at IASLC 2016 EFFICACY ENDPOINTS TTFIELDS WITH PEMETREXED AND CISPLATIN OR CARBOPLATIN 1 PEMETREXED AND CISPLATIN-ALONE HISTORICAL RESULTS 2 Median PFS 7.3 months 5.7 months Median OS Not yet reached 12.1 months One-year survival rate 79.7% 50.3% Novocure, Ltd. Safety and Efficacy of TTFields (150 khz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2018 Jan]. Available from: NLM Identifier: NCT Cerasoli, G.L. International Association for the Study of Lung Cancer. OA22.01 STELLAR Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma. Oral Session: Novel Trials and Biomarkers in Malignant Pleural Mesothelioma. Wednesday, Dec. 7, 2016, 2:20 p.m. CET 2. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma J Clin Oncol Jul 15;21(14): doi: /JCO
Novocure (NVCR) overview. updated January 2018
Novocure (NVCR) overview updated January 2018 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans
More informationNovocure (NVCR) overview. updated August 2018
Novocure (NVCR) overview updated August 2018 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and
More informationNovocure (NVCR) overview. updated July 2018
Novocure (NVCR) overview updated July 2018 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and
More informationNovocure. 37 th annual J.P. Morgan Healthcare Conference January 9, Bill Doyle Executive Chairman
Novocure 37 th annual J.P. Morgan Healthcare Conference January 9, 2019 Bill Doyle Executive Chairman forward-looking statements This presentation contains certain forward-looking statements with respect
More informationNovocure (NVCR) overview. updated November 2018
Novocure (NVCR) overview updated November 2018 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans
More informationWashington,D.C FORM8-K. NovoCureLimited. (Exactnameofregistrantasspecifiedinitscharter) Jersey (StateorOtherJurisdiction
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13OR15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):August15,2016
More informationFACT SHEET. About Optune
About Optune Optune is the Tumor Treating Fields (TTFields) delivery system that is approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with glioblastoma.
More informationNovocure. updated January 2019
Novocure updated January 2019 forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives,
More informationFirst glance at. Optune TM
For newly diagnosed or recurrent GBM First glance at Optune TM Actor portrayals Indications for Use Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed
More informationManagement guidelines for dermatologic adverse events (daes)
Management guidelines for dermatologic adverse events (daes) Brian is an Optune patient. A healthcare provider s guide to identifying, preventing, and managing daes for patients using Optune Indications
More informationLearning About Optune. Understanding Optune. A guide for patients and their caregivers. Actor portrayals
Learning About Optune Understanding Optune A guide for patients and their caregivers Actor portrayals Indications For Use Optune is intended as a treatment for adult patients (22 years of age or older)
More informationJosh is JB s brother and caregiver.
PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*
More informationELECTRIC TUMOR TREATMENT FIELDS
ELECTRIC TUMOR TREATMENT FIELDS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationA guide to scalp care and proper transducer array placement
A guide to scalp care and proper transducer array placement Actor portrayals This information is not intended to take the place of your physician s advice. Make sure you speak with your physician to determine
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory
More information5-year survival results
First glance at Optune FDA-approved for GBM Discovering Optune Inside: 5-year survival results in newly diagnosed GBM Brian, Xuan, Pat, Marcia, and Eugene are on Optune 1. How would Optune fit into my
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description Electric tumor treating
More informationUnderstanding Optune. A guide for patients and their caregivers. Inside: 5-year survival results in newly diagnosed GBM
Understanding Optune Learning About Optune A guide for patients and their caregivers Inside: 5-year survival results in newly diagnosed GBM Marcia is on Optune. BT is her husband. What is Optune approved
More informationNOVOCURE 2016 ANNUAL REPORT
NOVOCURE 2016 ANNUAL REPORT who we are 450+ 2 4 EMPLOYEES FDA-APPROVED INDICATIONS CURRENTLY ACTIVE MARKETS INNOVATIVE BREAKTHROUGHS Novocure is developing a profoundly different cancer treatment centered
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationMedical Necessity Guideline
(MNG) Title: Electric Tumor Treatment Field Therapy MNG #: 003 SCO One Care Prior Authorization Needed? Yes No Clinical: Operational: Informational: Medicare Benefit: Yes No Last Revised Date: 1/25/2019;
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationpatientforward Novocure 2015 Annual Report
patientforward Novocure 2015 Annual Report patientforward We are pursuing dramatic improvements in cancer patient survival while maintaining quality of life using a novel technology that changes the way
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationElectrical Stimulation Device Used for Cancer Treatment
Electrical Stimulation Device Used for Cancer Treatment OPTUNE (NOVOTTF 100A SYSTEM) For any item to be covered by The Health Plan, it must: 1. Be eligible for a defined Medicare or The Health Plan benefit
More informationbuilding a global oncology platform
building a global oncology platform NOVOCURE 2017 ANNUAL REPORT 04 explore our world 06 letter to our shareholders 08 company highlights CONSOLIDATED STATEMENT OF OPERATIONS 10 driving commercial adoption
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationDescription. Section: Durable Medical Equipment Effective Date: January 15, 2016 Subsection: Original Policy Date: December 6, 2013 Subject:
Last Review Status/Date: December 2015 Page: 1 of 9 Description multiforme is the most common and deadly malignant brain tumor. It has a very poor prognosis and is associated with low quality of life during
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTumor-Treating Fields Therapy
Tumor-Treating Fields Therapy Policy Number: 1.01.29 Last Review: 12/2018 Origination: 12/2013 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 26, 2013 Most Recent Review Date (Revised): November 26, 2013 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationTumor-Treatment Fields Therapy for Glioblastoma
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationRelated Policies None
Medical Policy MP 1.01.529 Tumor -Treatment Fields Therapy for Glioblastoma BCBSA Ref. Policy: 1.01.29 Last Review: 06/27/2018 Effective Date: 06/27/2018 Section: Durable Medical Equipment Related Policies
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationCancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results. Madrid, March 2015
1 Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results Madrid, March 2015 2 Cancer Treatments Surgical - whenever possible, Effective mostly in Early stages,
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationCorporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationJefferies Global Healthcare Conference New York 2014
Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationELECTRIC TUMOR TREATMENT FIELD THERAPY
UnitedHealthcare Commercial Medical Policy ELECTRIC TUMOR TREATMENT FIELD THERAPY Policy Number: 2017T0582B Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationSirtex Medical Limited (ASX:SRX)
Sirtex Medical Limited (ASX:SRX) Macquarie Australia Conference Mr Gilman Wong, CEO Dr David Cade, CMO Sydney, 8 th May 2014 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1 Understanding
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationNews Release. Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab.
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationELECTRIC TUMOR TREATMENT FIELD THERAPY
UnitedHealthcare Oxford Clinical Policy ELECTRIC TUMOR TREATMENT FIELD THERAPY Policy Number: CANCER 039.2 T2 Effective Date: December 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More information